Erschienen in:
27.01.2018 | Clinical study
Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma
verfasst von:
Anne-Sophie Hamy, Giang-Thanh Lam, Enora Laas, Lauren Darrigues, Thomas Balezeau, Julien Guerin, Alain Livartowski, Benjamin Sadacca, Jean-Yves Pierga, Anne Vincent-Salomon, Florence Coussy, Veronique Becette, Hélène Bonsang-Kitzis, Roman Rouzier, Jean-Guillaume Feron, Gabriel Benchimol, Marick Laé, Fabien Reyal
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 2/2018
Einloggen, um Zugang zu erhalten
Abstract
Purpose
Few studies evaluated the prognostic value of the presence of lymphovascular invasion (LVI) after neoadjuvant chemotherapy (NAC) for breast cancer (BC).
Methods
The association between LVI and survival was evaluated in a cohort of BC patients treated by NAC between 2002 and 2011. Five post-NAC prognostic scores (ypAJCC, RCB, CPS, CPS + EG and Neo-Bioscore) were evaluated and compared with or without the addition of LVI.
Results
Out of 1033 tumors, LVI was present on surgical specimens in 29.2% and absent in 70.8% of the cases. Post-NAC LVI was associated with impaired disease-free survival (DFS) (HR 2.54; 95% CI 1.96–3.31; P < 0.001), and the magnitude of this effect depended on BC subtype (Pinteraction = 0.003), (luminal BC: HR 1.83; P = 0.003; triple negative BC: HR 3.73; P < 0.001; HER2-positive BC: HR 6.21; P < 0.001). Post-NAC LVI was an independent predictor of local relapse, distant metastasis, and overall survival; and increased the accuracy of all five post-NAC prognostic scoring systems.
Conclusions
Post-NAC LVI is a strong independent prognostic factor that: (i) should be systematically reported in pathology reports; (ii) should be used as stratification factor after NAC to propose inclusion in second-line trials or adjuvant treatment; (iii) should be included in post-NAC scoring systems.